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Introduction  
Lipid myopathies (LMs) are a multi-systemic 
heterogenous group of lipid metabolism disorders caused 
by defects in oxidation of fatty acids and divided into 
two groups. Muscle symptoms could fluctuate or be 
stable. Constant or progressive proximal and axial muscle 
weakness associated with or without metabolic crisis, is 
often seen in patients with lipid storage myopathy (LSM) 
such as primary carnitine deficiency (PCD) or multiple 
acyl-coenzyme A dehydrogenase deficiency disorder 
(MADD), while rhabdomyolysis triggered by fasting, 
fever, or physical activity usually occurs in the patients with 
disorders affecting intramitochondrial fatty acid transport 
and β-oxidation, such as carnitine palmitoyltransferase II 
deficiency (CPT2), mitochondrial trifunctional protein 
deficiency and very-long-chain acyl-CoA dehydrogenase 
deficiency (VLCAD). The most common types of LSMs 
are MADD, PCD, and neutral lipid storage disease (NLSD) 
with or without ichthyosis. They are readily diagnosed 
by muscle biopsy with vacuolar myopathy appearance 
and positive oil red O or Sudan black stains. Under the 
electron microscope, the lipid droplets seem empty 
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Abstract
Background: Lipid storage myopathies (LSMs) are rare diseases. The phenotype and genotype 
of lipid metabolism disorders are heterogeneous and divided into two major groups. Constant 
or progressive proximal and axial muscle weakness associated with or without metabolic crisis, 
is often seen in patients with LSM such as primary carnitine deficiency (PCD) or multiple acyl-
coenzyme a dehydrogenase deficiency disorder (MADD). On the other hand, rhabdomyolysis 
triggered by fasting, fever, or physical activity usually occurs in patients with disorders affecting 
intramitochondrial fatty acid transport and β-oxidation, such as carnitine palmitoyltransferase II 
deficiency (CPT2), mitochondrial trifunctional protein deficiency and very-long-chain acyl-CoA 
dehydrogenase deficiency (VLCAD).
Methods: In this cross-sectional study, we summarized the clinical profiles and muscle histology of 
64 Iranian patients diagnosed with LSM by muscle biopsy. These patients were selected from 3000 
patients referred for muscle biopsy to Toos and Mofid children’s hospitals during 2010 to 2016. Their 
affected siblings were also added to the study.
Result: In our study 45.3% of the patients were men and 54.7% were women. Mean age of the 
patients was 27.05 years (SD: 14.26) and the mean age of onset of symptoms in these patients was 
20.94 (SD: 14.25) years.  Most patients (70.3%) had proximal weakness and no bulbar involvement. 
Only 9.3% of the patients had a positive family history.
Conclusion: LSMs are not uncommon in Iran and their phenotype can mimic inflammatory myopathy 
or limb girdle muscular dystrophy. Overall the demographic and clinical features of LSMs in Iranian 
patients were similar to prior reports.
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without a limiting membrane. They are lying between the 
myofibrils and in subsarcolemmal spaces, often adjacent 
to the mitochondria. But lipid droplets could be little or 
even not identified in muscle biopsy of the patients with 
the defects of fatty acid transport and β-oxidation. Fatty 
acids are not used to initiate activity but are used after 
20-30 minutes and are the main energy source for muscles 
after one hour. Hence during long-term activities and in 
resting state lipids would develop energy for muscles. So 
it is rational that lipid metabolism disorders occur after 
long-term activities and/or fasting. 1-7 
This study would help developing a pathological 
and clinical information database according to the 
geographical distribution based on the diagnosis of LSM 
on muscle biopsies to prepare possible and appropriate 
treatment opportunities.
Materials and Methods 
This was a cross-sectional study. These patients were 
selected from 3000 muscle biopsy reports from Toos 
and Mofid children’s hospitals during 2010-2016. Their 
affected siblings were also added to the study. Sixty-
four patients were studied. The pathological and clinical 
information of the patients were extracted from existing 
medical reports.
Data were analyzed using SPSS software, version 
22. Chi-square, Fisher’s exact, and t tests were used as 
appropriated. 
Results
In our study, there were 29 (45.3%) men and 35 (54.7%) 
women. The mean age of the patients was 27.05 (SD: 
14.26). The youngest patient was 2 years and the oldest one 
was 63 years old. The mean duration between diagnosis 
and onset of symptoms was three years and nine months 
with median of 1 year (range from 2 months to 18 years). 
The mean age at onset of symptoms was 20.94 years (SD: 
14.25). The youngest patient had symptoms since birth 
and the latest age of onset of symptoms was 62 years.
Most patients (70.3%) had proximal weakness. 3.1% 
had distal weakness and the other 26.6% had generalized 
weakness without any statistically significant difference 
between the men and women (P = 0.974). 10.9% of the 
patients had bulbar involvement without any significant 
difference between men and women (P = 0.489).
15 (23%) patients had positive family history in first 
degree relatives and 6 (9.3%) had positive family history 
in second degree relatives and most of the parents had no 
familial relationships. The most common site of muscle 
biopsies (0.35%) was biceps muscle. The rest were taken 
from deltoid, vastus lateralis, quadriceps, anterior tibialis, 
and gastrocnemius muscles.
In our study the common histopathological findings 
were diversity in size of fibers and round or angular 
atrophic fibers. Many fibers had multiple clear round 
cytoplasmic or sub-sarcolemmal vacuoles in various 
sizes that were mainly small (Figure 1a). These vacuoles 
were almost all labelled with Oil-red-O stain (Figure 
1b). Necrotic fibers were seen in only two (3.1%) and 
myophagocytosis and nuclear clumps were present in 7 
(10%) and one (1.5%) patient, respectively. Endomysial 
connective tissue did not increase in any patient. There 
was no fiber type grouping, no inflammation and no 
adipose tissue replacement. In the NSLD subtype, red 
rimmed vacuoles were seen in the muscle biopsies of two 
(3.1%) patients (figure 1c), of which one had ichthyosis. 
Discussion
LSM is rare with an incidence rate of 1/40 000 births for 
primary systemic carnitine deficiency in Japan. This rate 
Figure 1. (a) Vacuolar myopathy with numerous cytoplasmic 
vacuoles (Hematoxylin and eosin ×400). (b) Almost all 
cytoplasmic vacuoles are stained (Oil-red-O ×400). (c) Red-
rimmed vacuoles are seen accompanied by clear cytoplasmic 
vacuoles (modified Gomori Trichrome ×400).
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is 1/100 000 births in the United States and 1/500 births 
in Faeroe Island. The birth prevalence rate of PCD is 
1/ 21 000 births in Minnesota.8,9 The prevalence rate of 
MADD is 1/15 000 births to 1/20 000 births in United 
States. It seems that MADD is the most common type of 
LSM in Iran.4 Neutral LSMs are less assessed and probably 
1/one million births with 50 reported cases 10 
The phenotype of LSM is heterogeneous, and in 
childhood, brain and liver involvement are more 
prominent. Adulthood onset forms are less severe 
with muscle involvement. Infantile presentations are 
hypotonia, hypoglycemic hypoketotic, encephalopathy, 
hepatomegaly, and cardiomyopathy. The initiation 
symptoms in adults are more incidious  with or without 
metabolic crisis.11  Few studies have been reported 
from India. Five cases of carnitine deficiency myopathy 
were reported of which three were LSM, and one had 
pancreatitis, and one had hepatic encephalopathy.12,13
All our patients had muscle weakness, most of which 
(70%) were proximal and 3.1% were distal and the others 
were generalized. Ohkuma and colleagues reported 
a 55% weakness rate which was mainly proximal or 
generalized.14   We  found that 10.9% of the patients had 
bulbar involvement. Another study  assessed 9639 muscle 
biopsies and LSM in 47 (0.5%) biopsies. They reported no 
sex difference similar to our study. The age of onset was 
37-75 years and 8 out of 47 patients had a positive family 
history.14
Early MADD is characterized with hypotonia, 
hepatomegaly, non-hypoketotic hypoglycemia, and 
metabolic acidosis with early neonatal death. The late 
onset type presents with proximal myopathy. The free 
carnitine level is normal or reduced but acylcarnitine with 
medium to long chain is increased. Muscle biopsies are 
similar to PCD. Final diagnosis is with ETFB, ETFA, and 
ETFDH gene studies. Therapeutic response to riboflavin 
is dramatic.4 NLSD could present with ichthyosis, mild 
myopathy, hepatomegaly, visual symptoms, sensorineural 
hearing loss, short stature, and mental retardation. 
Ichthyosis is usually seen as nonbullous congenital 
ichthyosiform erythroderma. Cardiomyopathy is seen 
in NLSD with ichthyosis but sensorineural disorder and 
mental retardation are more common in NLSD without 
ichthyosis. In Jordan anomaly fat deposition in leukocytes 
could be seen even in pre-clinical state. Patients with 
NLSD occasionally have rimmed vacuoles in muscles.15 
Carnitine deficiency may present as myopathy with 
decreased muscle carnitine. The systemic form has muscle 
weakness and recurrent hepatic encephalopathy with 
decreased carnitine in the muscle, plasma, and liver.16,17 
The hepatic enzymes and CPK are raised. Severe decrease 
of free carnitine and acylcarnitine are seen in PCD.12 
Also 4.7% of the patients had a positive family history 
and 95.3% did not. Ohkuma et al also reported similar 
results.14 We found that 11 (17.2%) patients had parents 
who were first degree relatives and 5 (7.8%) were second 
degree relatives.
Conclusion
The results of our study showed that LSMs are not 
uncommon in Iran and overall demographic and clinical 
feature of LSMs in Iranian patients is similar to prior 
reports. Proximal weakness is seen in most patients, so 
phenotype of these patients mimics limb girdle muscular 
dystrophies or inflammatory myopathies. Positive family 
history and having first degree relative status in parents 
were not seen frequently. We found that sex and clinical 
presentation had no association with the disease. However, 
further studies with larger sample size, and reporting the 
results of genetic evaluation are recommended to attain 
more definite results.
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